Skip to main content
Premium Trial:

Request an Annual Quote

Aurora Alum Thomas Klopack Appointed CEO of Aclara

NEW YORK, March 20 - Aclara Biosciences has appointed Thomas Klopack CEO, the company said today.


Klopack, who was COO of Aurora Biosciences from 1998 until 2002, fills a position that has gone through a bit of musical chairs in the past few months: CEO Joseph Limber left last December, and Ed Hurwitz, a board member, was appointed interim CEO at the time, then stepped down Feb. 21. The company temporarily filled the management gap by bringing back Limber and recruiting board member Andre Marion to lead the company together as "the office of the president".


These changes come as the company shifts from a focus on microfluidics to assays that can be run on standard sequencing equipment, Jon Miller, director of corporate development, told GenomeWeb last month.


Klopack managed  the operations of Aurora, and managed integration of operations after the company was acquired by PanVera in 2001, Aclara said. Klopack previously worked at Raychem from 1979 to 1998, and holds an MBA from HarvardBusinessSchoolas well as a BS in engineering from Carnegie-MellonUniversity.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.